Abstract：Objective Evaluation the Fractionated Stereotactic Radiotherapy (FSRT) for the patients with small-cell lung cancer (SCLC) after the whole brain radiotherapy (WBRT) failure. Methods We retrospectively analyzed 35 patients with brain metastases from small-cell lung cancer treated with linear accelerator FSRT after the WBRT failure. Multivariate analysis was used to determine significant prognostic factor related to survival. Results The following-up rate was 100%.The median following-up time was 11 months. The median over-all survival (OS) time was 10.3(1－30) months after FSRT. Controlled extra cranial disease was the only identified significant predictor of increased median OS time (χ2=4.02, P=0.045). The median OS time from the diagnosis of brain metastasis was 22(6－134) months. 14 patients died from brain metastasis, 14 from extra-cranial progression, 1 from leptomeningeal metastases, and 3 from other causes. Local control at 6 months and 12 months was 91% and 76%, respectively. No significant late complications. New brain metastases outside of the treated area developed in 17% of patients at a median time of 4(2－20) months;all patients had received previous WBRT. Conclusions Fractionated stereotactic radiotherapy was safe and effective treatment for recurrent small-cell lung carcinoma brain metastases.
. Fractionated stereotactic radiotherapy for recurrent small cell lung cancer brain metastases after whole brain radiotherapy[J]. Chinese Journal of Radiation Oncology, 2012, 21(1): 20-22.
[1] Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin,2005,55:74-108. [2] Slotman BJ, Faivre-Finn C, Kramer GW, et al. Prophylactic cranial irradiation in patients with extensive disease caused by small-cell lung cancer responsive to chemotherapy:fewer symptomatic brain metastases and improved survival. Ned Tijdschr Geneeskd,2008,152:1000-1004. [3] Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases:phase Ⅲ results of the RTOG 9508 randomised trial. Lancet,2004,363:1665-1672. [4] Sperduto PW, Berkey B, Gaspar LE, et al. A new prognostic index and comparison to three other indices for patients with brain metastases:an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys,2008,70:510-514. [5] Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med,1990,322:494-500. [6] Arriagada R, Le Chevalier T, Borie F, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst,1995,87:183-190. [7] Wegner RE, Olson AC, Kondziolka D, et al. Stereotactic radiosurgery for patients with brain metastases from small cell lung cancer. Int J Radiat Oncol Biol Phys,2011,81:e21-e27. [8] Sheehan J, Kondziolka D, Flickinger J, et al. Radiosurgery for patients with recurrent small cell lung carcinoma metastatic to the brain:outcomes and prognostic factors. J Neurosurg,2005,102 Suppl:247-254. [9] Sperduto PW, Chao ST, Sneed PK, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases:a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys,2010,77:655-661.
2012, Vol. 21 
